Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Elekta AB (publ)
  6. News
  7. Summary
    EKTA B   SE0000163628

ELEKTA AB (PUBL)

(EKTA B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Elekta : optimizes treatment times for cancer patients via proactive service innovation

07/07/2021 | 01:31am EDT

Elekta in the forefront of service innovation through first radiotherapy system availability patent

STOCKHOLM, July 7, 2021 - For the last several years, Elekta (EKTA-B.ST) has invested substantially in digitized service solutions to keep critical treatment machines up and running at cancer clinics, thereby ensuring that patients receive timely radiotherapy. Among these solutions is the remote exchange of technical system data between Elekta remote service centers and linear accelerators installed at hospitals worldwide.

Using Elekta IntelliMax® real-time, remote system data monitoring, Elekta keeps a watchful eye on more than 80 percent of the company's linear accelerators installed around the world. IntelliMax constantly tracks these systems' functionality and technical status to ensure timely prevention or repair of issues. Elekta recently received its first patent for an IntelliMax capability that can help radiotherapy departments preserve the functionality of a crucial component of the technology used to treat patients.

Service innovation supports Access 2025 strategy
"Innovations such as IntelliMax are in harmony with our overall service strategy," says Paul Bergström, Executive Vice President, Global Service. "As our technology advances, it is critical to ensure its serviceability and maintenance progresses. Elekta is changing the equipment service paradigm - rather than responding reactively, our service model is centered on our strategy of lifelong partnership with our customers, proactively ensuring treatment systems are available when needed. Through IntelliMax, we can attend to systems during hours when it's convenient to our customers and, through this, create increased access for patients."

IntelliMax enables remote as well as onsite proactive system maintenance. In 2020, IntelliMax ensured that more than 200,000 patient treatment slots could continue without interruption.

"This patent for Elekta service is a fantastic milestone on our digitalization journey," adds Paul Bergström. "It is the first of several pending patent applications focused on improving the serviceability of our solutions. We are going to improve the 'predictability-to-treat' for customers - in other words, giving them the certainty that the treatment system is available for clinical use if and when they need it for life-saving, life-prolonging cancer treatments."

Learn more about IntelliMax at elekta.com/IntelliMax.

# # #

For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com  
Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,400 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

https://news.cision.com/elekta/r/elekta-optimizes-treatment-times-for-cancer-patients-via-proactive-service-innovation,c3380773

https://mb.cision.com/Main/35/3380773/1441657.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about ELEKTA AB (PUBL)
09/02ELEKTA : acquires Turkish distributor to strengthen market position
AQ
09/02ELEKTA AB (OM : EKTA B) acquired Özyürek Mümessillik ve Dis Ticaret A.S.
CI
08/31ELEKTA : Unity MR-Linac featured in 72 abstracts at European radiation oncology congress
AQ
08/31Elekta Unity MR-Linac Featured in 72 Abstracts At European Radiation Oncology Congress
CI
08/26ELEKTA : Board announces establishment of philanthropic Elekta Foundation
AQ
08/26ELEKTA AB (PUBL) : Ex-dividend day for interim dividend
FA
08/25GLOBAL MARKETS LIVE : Kering, Delta Air Lines, Pfizer, Moderna, Sony...
08/25ELEKTA : Report from the Annual General Meeting 2021 in Elekta
AQ
08/25Elekta AB Approves Dividend, Payable on 1 September 2021 and on 3 March 2022
CI
08/25Elekta AB Resolves on Dividend into Two Payments, Payable on 1 September 2021 and on 3 ..
CI
More news
Financials
Sales 2022 14 887 M 1 719 M 1 719 M
Net income 2022 1 372 M 158 M 158 M
Net Debt 2022 857 M 98,9 M 98,9 M
P/E ratio 2022 29,1x
Yield 2022 2,02%
Capitalization 39 966 M 4 628 M 4 616 M
EV / Sales 2022 2,74x
EV / Sales 2023 2,51x
Nbr of Employees 4 000
Free-Float 93,8%
Chart ELEKTA AB (PUBL)
Duration : Period :
Elekta AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELEKTA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 104,60 SEK
Average target price 116,08 SEK
Spread / Average Target 11,0%
EPS Revisions
Managers and Directors
Gustaf Salford President & Chief Executive Officer
John Adebńck Chief Financial Officer & Group Treasurer
Laurent Leksell Chairman
Steven Mark Wort Chief Operating Officer
Caroline Mofors Chief Compliance & Integrity Office, Senior VP
Sector and Competitors
1st jan.Capi. (M$)
ELEKTA AB (PUBL)-5.30%4 628
THERMO FISHER SCIENTIFIC30.24%239 289
DANAHER CORPORATION45.91%232 039
INTUITIVE SURGICAL, INC.27.72%124 326
SIEMENS HEALTHINEERS AG41.83%78 425
EDWARDS LIFESCIENCES CORPORATION31.16%75 435